The Howard Gilman Institute for Valvular Heart Disease
blank top line
home
heart valve disease
patient care
about the institute
research
conference
in the news
contact us
contact us

Research

IN THIS SECTION

1. Overview

2. Research Focus

3. Projects

4. Publications

 

Publications

 

2006 - 2007


2007

Borer JS, Supino PG. Radionuclide angiography part ii: equilibrium imaging in Nuclear Cardiac Imaging: Principles and Applications, 4th Edition (Iskandrian A, ed), Oxford, New York, 2007, in press

Borer JS (Guest Editor). If inhibition by ivabradine. Drugs 2007; Supplement 2:1-49. (Borer JS. Forward, pp1-2). 

DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs 2007;67 (Suppl 2):15-24.

Borer JS. If inhibition in challenging cardiac conditions: evidence and future prospects. Medicographia 2007; 29:295-300.

Borer JS. Cellular and molecular basis of myocardial dysfunction in valvular heart diseases: implications for therapeutic decisions. Hjerteforum 2007, in press.

Borer JS. Heart rate and ischemic heart disease, in Heart Rate Management (Benetos A, ed), Wolters Kluwer Health (Paris), 2007, pp. 71-84.

Borer JS. Angiotensin converting enzyme (ACE) inhibition: a landmark advance in treatment for cardiovascular diseases. European Heart Journal 2007; Supplements 9;Suppl E: E2-E9.

Supino PG, Borer JS. Teaching clinical research methodology to the academic medical community: a fifteen-year retrospective of a comprehensive curriculum. Medical Teacher 2007; 29:346-352.

Supino PG, Borer JS, Herrold EM, Hochreiter CA, Preibisz J, Schuleri K, Roman MJ, Kligfield P. Prognostic impact of systolic hypertension on asymptomatic patients with chronic severe aortic regurgitation and initial normal left ventricular performance at rest. American Journal of Cardiology 2005; 96:964-970.

Borer JS. Indications for operation for aortic regurgitation in asymptomatic patients in Harrison’s Online (Harrison’s Principles of Internal Medicine on line updates, Cardiovascular Disease) (Braunwald E, ed), McGraw-Hill (New York), 2007 (5/4/07), (www.accessmedicine.com), pp. 1-7.

Truter SL, Catanzaro DF, Borer JS, Lee E, Gupta A, Supino PG, Carter J, Herrold EM, Huang Z, Pitlor LL, Dumlao TF. Extracellular matrix remodeling in aortic regurgitation: role of mitogen-activated protein kinases. JACC, in review 2007

Borer JS, Supino PG. Radionuclide angiography. Equilibrium imaging in Nuclear Cardiac Imaging: Principles and Applications, 4th Edition (Iskandrian A, Garcia, EV eds), Oxford University Press, New York, 2007, pp. 515 – 540 (in press).

Friedewald V, Bonow RO, Borer JS, Carabello BA, Kleine P, Akins C, Roberts WC The Editor’s roundtable: cardiac valve surgery. American Journal of Cardiology 2007; 99:1269-1278.

Supino PG, Borer JS. A new course on hypothesis and protocol development. Medical Education 2007; 41:525-526.

Borer JS, Herrold EM, Carter JN, Catanzaro DF, Supino P. Cellular and molecular basis of remodelling in valvular heart diseases. Heart Failure Clinics 2006; 2: 415-424.

Supino PG, Borer JS, Schuleri K, Gupta A, Hochreiter C, Kligfield P, Herrold EM, Preibisz J, Bomsztyk M. Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation. American Journal of Cardiology 2007; 100:1274-1281

Borer JS, Pouleur H, Abadie E, Follath F, Wittes J, Lipicky RJ, Pfeffer MA, Pitt B, Zannad F. Assessment of cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. European Heart Journal 2007;28:1904-1909.

Lewis RM, Gordon DJ, Poole-Wilson PA, Borer JS, Zannad F. Similarities and Differences in Design Considerations for Cell Therapy and Pharmacologic Cardiovascular Clinical Trials. Cardiology 2007, in press.

Bacchetta MD, Salemi A, Milla F, Hong MK, Tio F, Zhou Y, Chen R, Yu F, Southard E, Lee LY, Mack CA, Krieger KH, Isom OW, Ko W, Borer JS, Catanzaro DF. Low-dose spironolactone: effects on artery-to-artery vein grafts and percutaneous coronary intervention sites.Circulation Research 2007, in review.

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez-Sendon JL, Steg PG, Tardif J-C, Tavazzi L, Tendera M. Resting heart rate: a forgotten factor in cardiovascular disease? Journal of the American College of Cardiology 2007, 50:823-830.

White WB, West CR, Borer JS, Gorelick PS, Lavange LM, Pan SX, Weiner E, Verburg K.Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. American Journal of Cardiology 2007, 99:91-98.

Sasson L, Ureche A, Manolache G, Ciubotaru A, Borer JS, Schachner A. Nitric oxide synthase inhibitor (MTR-105) during open heart surgery: a double blind placebo controlled study of hemodynamic effect and safety. Chest, 2007, in review.

2006

Borer JS, Herrold EM, Carter JN, Catanzaro DF, Supino P. Cellular and molecular basis of remodelling in valvular heart diseases. Heart Failure Clinics 2006; 2: 415-424.

Supino PG, Borer JS. Epidemiology of valvular heart diseases: a growing public health problem. Heart Failure Clinics 2006; 2:379-393.

Fox KM, Ferrari R, Yusuf S, Borer, JS. Should ACE inhibitors be used to improve outcome in patients with coronary disease and preserved LV function? European Heart Journal 2006; 27:2154-2157.

Borer JS. Therapeutic effects of If blockade: evidence and perspective. Pharmacological Research 2006; 53:440-446.

Corbett JR, Akinboboye OO, Bacharach SL, Borer JS, Botvinick EH, DePuey EG, Ficaro EP, Hansen CL, Henzlova MJ, Van Kriekinge S. Equilibrium radionulide angiocardiography. Journal of Nuclear Cardiology 2006; 13:e56-79.

Borer JS. Can Ifinhibition help in angina? Dialogues in Cardiovascular Medicine 2006; 11:21-29.

Borer JS. Cyclo-oxygenase inhibition: what should we do to resolve the confusion? An American Perspective. Journal of Cardiovascular Pharmacology, 2006; 47(Suppl. 1):S87-S91.

Borer JS. Clinical effect of “pure” heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine. Advances in Cardiology, 2006, 43:54-64.

Borer JS. Valvular heart disease, in Principles and Practice of Geriatric Medicine (Pathy MSJ, Morley JE, Sinclair S, eds), 4th Edition, Wiley (Chichester), 2006; 529-540. .

Gupta A, Carter J, Truter SL, Leer EH, Herrold EM, Borer JS. Cellular response of human cardiac fibroblasts to mechanically simulated aortic regurgitation. American Journal of Therapeutics 2006;13:8-11.

Borer JS, Truter SL, Supino PG, Herrold EM, Carter JN, Hochreiter CA, Heaphy J. Molecular and cellular pathophysiology: basis for pharmacological therapy in regurgitant valvular diseases? in Advances in Heart Disease: New Trends in Research, Diagnosis and Treatment (Kimchi A, ed), Medimond (Bologna) 2006, pp. 599-602.

Borer JS, Schuleri K. Myocardial remodeling: physiological and pathological, in Myocardial Remodeling: Mechanisms and Treatment (Greenberg B, ed), Taylor and Francis (New York), 2006; pp. 121-138.

 

 

< Prev Next >

 

blank
heart valve disease | patient care | about the institute | research | conference | news | contact us
The Howard Gilman Institute for Heart Valve Disease